Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 60
Filter
Add more filters

Publication year range
1.
Curr Gastroenterol Rep ; 22(5): 25, 2020 Mar 28.
Article in English | MEDLINE | ID: mdl-32222940

ABSTRACT

PURPOSE OF REVIEW: This review presents the available data regarding efficacy of nutritional therapy, highlighting clinical decision points and a strategy for reintroduction of foods following an elemental diet for treatment of eosinophilic gastrointestinal disorders. RECENT FINDINGS: Elemental and empiric elimination diets are highly effective treatments for eosinophilic gastrointestinal diseases. Standardization in the reintroduction phase, after utilizing the diet for disease remission, is lacking. Clinicians are confronted with multiple challenges regarding the best practice for food reintroduction and identification of potential dietary triggers including order of foods being challenged and duration between endoscopic procedures. Individualization is required for preference and adherence to optimize quality of life and treatment success for this burdensome and life altering immune driven gastrointestinal disorder. Age specific concerns for children, teenagers, and adults should be assessed using a patient centric approach.


Subject(s)
Enteritis/diet therapy , Eosinophilia/diet therapy , Food Hypersensitivity/diet therapy , Food, Formulated , Gastritis/diet therapy , Humans , Quality of Life , Risk Factors
2.
Pediatr Res ; 86(4): 505-509, 2019 10.
Article in English | MEDLINE | ID: mdl-31141816

ABSTRACT

BACKGROUND: The effectiveness of budesonide (BUD), a locally active steroid, on eosinophilic gastroenteritis (EGE) is not well understood. This study is to retrospectively evaluate the efficacy of BUD in children with EGE. METHODS: Forty-four children, diagnosed with EGE, were enrolled from 2013 to 2017 in our center. According to patients' preference, all the patients were treated with dietary elimination (DE) and montelukast therapy, or combined with prednisone (PRED)/BUD. Patients' clinical manifestations, treatments, and outcomes were reviewed from the medical records. Twenty-four patients (7 PRED, 7 BUD, 10 DE) received therapy for ≥8 weeks, followed by repeat endoscopy and biopsies. Histological response was defined as <20 eos/hpf (eosinophils per high-power field). RESULTS: Significant number of patients in DE+PRED (6/7, 85.7%) and DE+BUD (6/7, 85.7%) groups achieved histological response than in the DE group (3/10.30%) (p = 0.024). Mean post-treatment peak eos/hpf in the DE+PRED group was 16.57 ± 6.85 vs. 10.00 ± 5.07 in the DE+BUD group vs. 36.60 ± 24.57 in the DE group (p = 0.009). Change of eos/hpf from pre- to post-treatment was -49.86 ± 45.02 vs. -34.29 ± 23.44 in the BUD group vs. -0.3 ± 23.95 in the DE group (p = 0.011). There were no significant differences between DE+PRED and DE+BUD groups (p = 0.470, p = 0.363, respectively). CONCLUSION: BUD is effective in the treatment of EGE and has similar effectiveness with PRED.


Subject(s)
Budesonide/administration & dosage , Enteritis/drug therapy , Eosinophilia/drug therapy , Gastritis/drug therapy , Acetates/administration & dosage , Adolescent , Biopsy , Child , Child, Preschool , Cyclopropanes , Endoscopy , Enteritis/diet therapy , Eosinophilia/diet therapy , Eosinophils , Female , Gastritis/diet therapy , Humans , Infant , Male , Prednisone/administration & dosage , Quinolines/administration & dosage , Retrospective Studies , Sulfides , Treatment Outcome
3.
J Pediatr Gastroenterol Nutr ; 63(3): 336-9, 2016 09.
Article in English | MEDLINE | ID: mdl-27548247

ABSTRACT

OBJECTIVES: The aim of the present study was to describe the prevalence and clinical features of gastrointestinal (GI) eosinophilic inflammation among pediatric patients with intestinal failure (IF). METHODS: Medical records of all patients studied in our institution's IF program who underwent GI endoscopy over a 15-year period were reviewed, and clinical, pathologic, nutrition, and laboratory data collected. RESULTS: One hundred five patients underwent 208 GI endoscopic procedures with biopsy. The overall prevalence of eosinophilic inflammation, defined as increased eosinophils in at least 1 tissue type on at least 1 endoscopy, was 39 of 105 (37%). The tissue-specific prevalence of eosinophilic inflammation ranged widely, with the colon/rectosigmoid being the most common (18/68, 26%), followed by the esophagus (17/83, 20%), ileum (9/54, 17%), duodenum (4/83, 5%), and stomach (3/83, 4%). Higher peripheral eosinophil count and hematochezia were associated with eosinophilic inflammation in the colon (P = 0.002 and 0.0004, respectively). The use of a strict elemental diet for 3 months before endoscopy was not associated with a decreased frequency of eosinophilic inflammation in any tissue. CONCLUSIONS: Eosinophilic inflammation is a common histopathological finding in patients with IF. Colonic eosinophilic inflammation is associated with clinical symptoms of GI blood loss, and peripheral eosinophilia, and was not abrogated by a strict elemental diet.


Subject(s)
Enteritis/epidemiology , Eosinophilia/epidemiology , Gastritis/epidemiology , Child, Preschool , Endoscopy , Enteritis/complications , Enteritis/diagnosis , Enteritis/diet therapy , Eosinophilia/complications , Eosinophilia/diagnosis , Eosinophilia/diet therapy , Female , Gastritis/complications , Gastritis/diagnosis , Gastritis/diet therapy , Humans , Infant , Male , Parenteral Nutrition/adverse effects , Prevalence , Retrospective Studies , Risk Factors
4.
J Pediatr Gastroenterol Nutr ; 61(1): 56-64, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25699593

ABSTRACT

OBJECTIVES: Various dietary interventions have been used to treat patients with eosinophilic gastroenteritis (EGE). Concrete evidence as to the effectiveness of such treatments in inducing disease remission is, however, lacking. The aim of the study was to systematically review the efficacy of dietary therapies in inducing EGE remission. METHODS: We performed a systematic search for the MEDLINE, EMBASE, and SCOPUS libraries for studies investigating the efficacy of dietary interventions (in both histological and symptomatic remission) for children and adults with EGE and colitis. RESULTS: The search yielded 490 references; 30 were included in the review, with most of these references being "low-quality" individual cases or short case series. No significant publication bias was found. Elemental diets in children were linked to 75.8% of clinical improvement, but few of these patients underwent a histological evaluation. Allergy-testing results have been used scarcely in EGE. Empiric elimination of allergy-associated foods was the most commonly used option. The variable results in terms of symptom relief, however, were scarcely accompanied by histological confirmation. Clinical and methodological heterogeneity hindered the performance of quantitative summaries for the efficacy of dietary therapies in inducing disease remission. CONCLUSIONS: Symptomatic improvements reported for dietary treatment in EGE by most of the available literature are questionable because of the lack of objective evaluation of clinical changes and the very limited assessment of histological remission. Because of the relative lack of well-designed, high-quality studies, the unequivocal use of dietary treatment for patients with EGE and colitis cannot be supported. Further research should be undertaken.


Subject(s)
Enteritis/diet therapy , Eosinophilia/diet therapy , Gastritis/diet therapy , Food Hypersensitivity , Food, Formulated , Humans , Remission Induction
7.
WMJ ; 114(6): 271-3, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26854316

ABSTRACT

Collagenous gastritis is a rarely encountered disease entity first described in 1989, and it is very rarely reported in children. We report the case of a 13-year-old boy with clinical, endoscopic, and histological findings of collagenous gastritis who reported rapid and sustained symptom resolution on a gluten-free diet.


Subject(s)
Diet, Gluten-Free , Gastritis/diet therapy , Gastritis/diagnosis , Adolescent , Collagen , Diagnosis, Differential , Humans , Male
8.
Am J Gastroenterol ; 109(8): 1277-85, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24957155

ABSTRACT

OBJECTIVES: Eosinophilic gastritis (EG), defined by histological criteria as marked eosinophilia in the stomach, is rare, and large studies in children are lacking. We sought to describe the clinical, endoscopic, and histopathological features of EG, assess for any concurrent eosinophilia at other sites of the gastrointestinal (GI) tract, and evaluate response to dietary and pharmacological therapies. METHODS: Pathology files at our medical center were searched for histological eosinophilic gastritis (HEG) with ≥70 gastric eosinophils per high-power field in children from 2005 to 2011. Pathology slides were evaluated for concurrent eosinophilia in the esophagus, duodenum, and colon. Medical records were reviewed for demographic characteristics, symptoms, endoscopic findings, comorbidities, and response to therapy. RESULTS: Thirty children with severe gastric eosinophilia were identified, median age 7.5 years, 14 of whom had both eosinophilia limited to the stomach and clinical symptoms, fulfilling the clinicopathological definition of EG. Symptoms and endoscopic features were highly variable. History of atopy and food allergies was common. A total of 22% had protein-losing enteropathy (PLE). Gastric eosinophilia was limited to the fundus in two patients. Many patients had associated eosinophilic esophagitis (EoE, 43%) and 21% had eosinophilic enteritis. Response to dietary restriction therapy was high (82% clinical response and 78% histological response). Six out of sixteen patients had persistent EoE despite resolution of their gastric eosinophilia; two children with persistent HEG post therapy developed de novo concurrent EoE. CONCLUSIONS: HEG in children can be present in the antrum and/or fundus. Symptoms and endoscopic findings vary, highlighting the importance of biopsies for diagnosis. HEG is associated with PLE, and with eosinophilia elsewhere in the GI tract including the esophagus. The disease is highly responsive to dietary restriction therapies in children, implicating an allergic etiology. Associated EoE is more resistant to therapy.


Subject(s)
Enteritis/pathology , Eosinophilia/pathology , Gastritis/pathology , Adolescent , Child , Child, Preschool , Comorbidity , Enteritis/diet therapy , Enteritis/drug therapy , Eosinophilia/diet therapy , Eosinophilia/drug therapy , Female , Gastritis/diet therapy , Gastritis/drug therapy , Gastroscopy , Humans , Infant , Male , Treatment Outcome
9.
Minn Med ; 95(12): 43-4, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23346726

ABSTRACT

Elimination diets can be both a diagnostic tool and a therapeutic intervention for people with a suspected food sensitivity or allergy. They are clinically relevant not only for patients with functional gastrointestinal disorders but also for those with conditions where symptoms are refractory and a diagnosis is elusive. Elimination diets can help a physician make a diagnosis or identify an underlying cause of symptoms. The physician and team treating the patient can then use that information to recommend appropriate dietary and lifestyle changes as well as judicious drug therapy. This article describes the elimination/challenge diet approach and explains the rationale for undertaking it.


Subject(s)
Food Hypersensitivity/diet therapy , Food Hypersensitivity/diagnosis , Aged , Arthritis, Rheumatoid/diet therapy , Arthritis, Rheumatoid/etiology , Chronic Pain/diet therapy , Chronic Pain/etiology , Cooperative Behavior , Diagnosis, Differential , Fatigue/diet therapy , Fatigue/etiology , Female , Gastritis/diet therapy , Gastritis/etiology , Humans , Interdisciplinary Communication , Patient Care Team
10.
Eksp Klin Gastroenterol ; (2): 37-40, 2012.
Article in Russian | MEDLINE | ID: mdl-22808790

ABSTRACT

In work some, often meeting nosological forms urogenithal surgical diseases which last years frequently proceed against gastritises, stomach ulcer of a stomach and 12-perstnoj guts owing to increase of occurrence of the last are presented. For treatment various medicamentous schemes, which do-polnjajutsja rational diet-correction for the purpose of increase efficaci and qualities of treatment are used. The work purpose--to present features ratsional pathogenetic correctic a food at persons from an aggravation acid-deprndent to a pathology against constant reception prepara apropos urogenithal diseases.


Subject(s)
Azotemia/diet therapy , Gastric Acid/metabolism , Gastritis/diet therapy , Nephrotic Syndrome/diet therapy , Peptic Ulcer/diet therapy , Prostatitis/diet therapy , Azotemia/complications , Azotemia/metabolism , Feeding Behavior , Gastritis/complications , Gastritis/metabolism , Humans , Male , Nephrotic Syndrome/complications , Nephrotic Syndrome/metabolism , Peptic Ulcer/complications , Peptic Ulcer/metabolism , Prostatitis/complications , Prostatitis/metabolism , Quality of Life
12.
Nutrients ; 13(8)2021 Aug 14.
Article in English | MEDLINE | ID: mdl-34444949

ABSTRACT

The prevalence of gastritis in humans is constantly growing and a prediction of an increase in this health problem is observed in many countries. For this reason, effective dietary therapies are sought that can alleviate the course of this disease. The objective of this study was to determine the effect of chemically pure oat beta-glucan preparations with different molar masses, low or high, used for 30 days in patients with histologically diagnosed chronic gastritis. The study enrolled 48 people of both genders of different ages recruited from 129 patients with a gastritis diagnosis. Before and after the therapy, hematological, biochemical, immunological and redox balance parameters were determined in the blood and the number of lactic acid bacteria and SCFA concentrations in the feces. Our results demonstrated a beneficial effect of oat beta-glucans with high molar mass in chronic gastritis in humans, resulting in reduced mucosal damage and healthy changes in SCFA fecal concentration and peripheral blood serum glutathione metabolism and antioxidant defense parameters. This fraction of a highly purified oat beta-glucan is safe for humans. Its action is effective after 30 days of use, which sheds new light on the nutritional treatment of chronic gastritis.


Subject(s)
Avena , Gastritis/diet therapy , beta-Glucans/administration & dosage , Adult , Aged , Chronic Disease , Double-Blind Method , Fatty Acids, Volatile/metabolism , Feces/chemistry , Feces/microbiology , Female , Gastritis/microbiology , Humans , Lactobacillales/metabolism , Male , Middle Aged , Osmolar Concentration , Treatment Outcome , Young Adult
13.
Nutrients ; 13(6)2021 Jun 19.
Article in English | MEDLINE | ID: mdl-34205445

ABSTRACT

In the last decade, the role of nutritional management in pediatric gastrointestinal diseases has gained increasing popularity. Disease-specific diets have been introduced as conventional treatments by international guidelines. Patients tend to more willingly accept food-based therapies than drugs because of their relatively "harmless" nature. Apart from a diet's therapeutic role, nutritional support is crucial in maintaining growth and improving clinical outcomes in pediatric patients. Despite the absence of classical "side effects", however, it should be emphasized that any dietary modification might have negative consequences on children's growth and development. Hence, expert supervision is always advised, in order to support adequate nutritional requirements. Unfortunately, the media provide an inaccurate perception of the role of diet for gastrointestinal diseases, leading to misconceptions by patients or their caregivers that tends to overestimate the beneficial role of diets and underestimate the potential adverse effects. Moreover, not only patients, but also healthcare professionals, have a number of misconceptions about the nutritional benefits of diet modification on gastrointestinal diseases. The aim of this review is to highlight the role of diet in pediatric gastrointestinal diseases, to detect misconceptions and to give a practical guide for physicians on the basis of current scientific evidence.


Subject(s)
Gastrointestinal Diseases/diet therapy , Nutrition Therapy , Abdominal Pain , Animals , Cattle , Child , Child, Preschool , Diet , Enteritis/diet therapy , Enteritis/physiopathology , Eosinophilia/diet therapy , Eosinophilia/physiopathology , Food Hypersensitivity , Gastritis/diet therapy , Gastritis/physiopathology , Gastrointestinal Diseases/physiopathology , Gastrointestinal Microbiome/physiology , Health Knowledge, Attitudes, Practice , Humans , Infant , Infant, Newborn , Inflammatory Bowel Diseases/diet therapy , Inflammatory Bowel Diseases/physiopathology , Milk/adverse effects , Milk/immunology , Nutritional Requirements , Practice Guidelines as Topic , Probiotics
14.
Mol Nutr Food Res ; 65(5): e1901269, 2021 03.
Article in English | MEDLINE | ID: mdl-32780927

ABSTRACT

Inflammatory bowel disease (IBD) is characterized by chronic relapsing inflammation in the intestine. Given their role in regulation of inflammation, long-chain n-3 polyunsaturated fatty acids (PUFAs) represent a potential supplementary therapeutic approach to current drug regimens used for IBD. Mechanistically, there is ample evidence for an anti-inflammatory and pro-resolution effect of long-chain n-3 PUFAs after they incorporate into cell membrane phospholipids. They disrupt membrane rafts and when released from the membrane suppress inflammatory signaling by activating PPAR-γ and free fatty acid receptor 4; furthermore, they shift the lipid mediator profile from pro-inflammatory eicosanoids to specialized pro-resolving mediators. The allocation of long-chain n-3 PUFAs also leads to a higher microbiome diversity in the gut, increases short-chain fatty acid-producing bacteria, and improves intestinal barrier function by sealing epithelial tight junctions. In line with these mechanistic studies, most epidemiological studies support a beneficial effect of long-chain n-3 PUFAs intake on reducing the incidence of IBD. However, the results from intervention trials on the prevention of relapse in IBD patients show no or only a marginal effect of long-chain n-3 PUFAs supplementation. In light of the current literature, international recommendations are supported that adequate diet-derived n-3 PUFAs might be beneficial in maintaining remission in IBD patients.


Subject(s)
Fatty Acids, Omega-3/pharmacology , Gastritis/diet therapy , Gastrointestinal Microbiome/drug effects , Inflammatory Bowel Diseases/diet therapy , Animals , Diet, Western/adverse effects , Dietary Supplements , Eicosanoids/pharmacology , Fatty Acids, Omega-3/chemistry , Fatty Acids, Omega-3/physiology , Gastric Mucosa/drug effects , Gastric Mucosa/pathology , Gastritis/etiology , Gastrointestinal Microbiome/physiology , Humans
16.
Mol Nutr Food Res ; 64(8): e1900965, 2020 04.
Article in English | MEDLINE | ID: mdl-32032975

ABSTRACT

SCOPE: A high-salt diet is a cause of gastritis, but the associated mechanism remains unclear. Recent studies have shown that gastric flora is associated with a variety of stomach diseases, but it is not known whether gastric flora is involved in gastritis induced by a high-salt diet. METHODS AND RESULTS: Gastritis is successfully induced in C57BL/6 mice fed a high-salt diet (salt: 5% NaCl) for four weeks. Through 16S rRNA gene sequencing, the composition of the stomach microbiota of mice fed normal and high-salt diets are compared, the results of which show that the high-salt diet induces significant changes in the gastric flora. Phylogenetic investigation of communities by reconstruction of unobserved states (PICRUSt) is used to predict the function of the microbiota in the stomach of mice, and the results indicate that a high-salt diet leads to a decrease in the ability of the gastric microbiota to metabolize polysaccharides and vitamins. A buckwheat diet is used to treat gastritis. The results show gastritis induced by the high-salt diet is significantly alleviated, and the dysbiosis in the stomach also improved. CONCLUSION: Buckwheat diet may be one of the ways to prevent and treat gastritis caused by a high-salt diet.


Subject(s)
Dysbiosis/diet therapy , Fagopyrum , Gastritis/diet therapy , Gastritis/etiology , Sodium Chloride, Dietary/adverse effects , Animals , Cell Differentiation/drug effects , Diet/adverse effects , Dysbiosis/etiology , Gastritis/microbiology , Gastrointestinal Microbiome/drug effects , Gastrointestinal Microbiome/genetics , Gastrointestinal Microbiome/physiology , Male , Mice, Inbred C57BL , Spleen/cytology , Spleen/drug effects , Th17 Cells/drug effects
18.
Clin J Gastroenterol ; 12(6): 530-533, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31077082

ABSTRACT

Eosinophilic gastrointestinal disorders (EGID) comprise a spectrum of inflammatory diseases that can affect any segment of the gastrointestinal tract. The pathogenesis of these conditions is complex; differentiating between primary and secondary forms of these disorders can be clinically challenging. We report a case of primary EGID in a patient with remote parasite exposure, whose symptoms were initially attributed to irritable bowel syndrome. Endoscopy revealed the rare finding of EGID involving the entire gastrointestinal tract; symptoms improved with an elimination diet. This case raises the possibility of a link between prior parasite exposure and development of EGID, and underscores the necessity of exploring alternative diagnoses in patients with presumed IBS who present with severe symptoms.


Subject(s)
Colitis/parasitology , Enteritis/parasitology , Eosinophilia/parasitology , Eosinophilic Esophagitis/parasitology , Gastritis/parasitology , Toxocariasis , Colitis/diagnosis , Colitis/diet therapy , Dairy Products , Enteritis/diagnosis , Enteritis/diet therapy , Eosinophilia/diagnosis , Eosinophilia/diet therapy , Eosinophilic Esophagitis/diagnosis , Eosinophilic Esophagitis/diet therapy , Gastritis/diagnosis , Gastritis/diet therapy , Humans , Male , Middle Aged , Treatment Outcome
19.
Nutrition ; 54: 26-32, 2018 10.
Article in English | MEDLINE | ID: mdl-29729504

ABSTRACT

OBJECTIVE: Gastroesophageal reflux disease is very common in industrialized countries and rapidly and significantly increasing even in developing countries. The approach in this study is one not commonly found to date in the scientific literature. To assess the ability of reduced-carbohydrate diets and foods that are enriched with acid potential of hydrogen (pH; lemon and tomato) to quickly and exponentially reduce symptoms that are related to conditions such as gastritis and gastroesophageal reflux and unrelated to Helicobacter pylori. METHODS: After the administration of an anamnestic test, 130 patients were selected including 73 women and 57 men, 21 to 67 y, and with a gastritis diagnosis for 92 patients (56 women, 36 men) and reflux gastritis for 38 patients (17 women, 21 men). Study participants followed three dietary treatments in succession. Each treatment lasted 2 wk and treatments were separated by 2 wk of washout. The patients followed a diet that consisted primarily of proteins and fats and included the exponential reduction of glycides (simple and complex). In addition, the treatment provided for the daily intake of the juice of two lemons and approximately 100 g of fresh orange tomato without seeds eaten either raw or cooked and peeled. RESULTS: During treatment and at the end of 2 wk of treatment, the patients reported significant improvements including an almost total disappearance of symptoms that were related to the disease in question. CONCLUSIONS: This study shows that a carbohydrate-free diet and/or highly hypoglycidal diet that is enriched with acid pH foods appears to lead to a decrease in the pH of the gastric contents, thus inhibiting the further production of hydrochloric acid with a reduction or disappearance of heartburn symptoms that are typical of gastroesophageal diseases.


Subject(s)
Diet, Carbohydrate-Restricted/methods , Diet/methods , Gastritis/diet therapy , Gastroesophageal Reflux/diet therapy , Adult , Aged , Citrus/chemistry , Epoxy Compounds/analysis , Female , Fruit and Vegetable Juices/analysis , Gastric Acid/chemistry , Gastric Acidity Determination , Humans , Hydrogen-Ion Concentration , Solanum lycopersicum/chemistry , Male , Middle Aged , Propionates/analysis , Treatment Outcome , Young Adult
20.
Clin Nutr ; 36(4): 968-979, 2017 08.
Article in English | MEDLINE | ID: mdl-27654926

ABSTRACT

The digestive system provides nourishment to the whole body. Disorders in this system would result in many associated illnesses as the body is deprived of essential nutrients. Gastrointestinal diseases, in particular, gastric ulceration, inflammatory bowel diseases and colorectal cancer have become more prevalent in all population age groups. While this can be attributed to diet and lifestyle changes, the measures to combat these illnesses with conventional drugs is losing popularity owing to the harsh side effects, drug resistance and lack of patient compliance. The focus of this review is to endorse promising nutraceutical dietary components such as phytosterols, polyphenols, anthocyanins and polyunsaturated fatty acids and their synergistic value, in combination with conventional management of key gastrointestinal diseases. As most of these nutraceuticals are labile compounds, the need for protection and delivery using a carrier system is stressed and the methods for targeting to specific parts of the gastrointestinal tract are discussed. A section has also been devoted to perspectives on co-encapsulation methods of drugs and nutraceuticals using different particle systems. Multilayered carrier systems like double layered and core shell particles have been proposed as an exemplary system to co-encapsulate both drugs and nutrients while keeping them segregated.


Subject(s)
Complementary Therapies , Dietary Supplements , Evidence-Based Medicine , Gastrointestinal Agents/therapeutic use , Gastrointestinal Diseases/diet therapy , Nutritional Support , Colorectal Neoplasms/diet therapy , Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/prevention & control , Colorectal Neoplasms/therapy , Combined Modality Therapy , Complementary Therapies/trends , Diet, Healthy , Food-Drug Interactions , Gastritis/diet therapy , Gastritis/drug therapy , Gastritis/prevention & control , Gastritis/therapy , Gastrointestinal Diseases/drug therapy , Gastrointestinal Diseases/prevention & control , Gastrointestinal Diseases/therapy , Healthy Lifestyle , Helicobacter Infections/diet therapy , Helicobacter Infections/drug therapy , Helicobacter Infections/prevention & control , Helicobacter Infections/therapy , Humans , Inflammatory Bowel Diseases/diet therapy , Inflammatory Bowel Diseases/drug therapy , Inflammatory Bowel Diseases/prevention & control , Inflammatory Bowel Diseases/therapy , Nutritional Support/trends
SELECTION OF CITATIONS
SEARCH DETAIL